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Abstract
Large anionic multilamellar liposomes containing 71% membrane cholesterol (MLV) caused complement (C) activation in
human serum in vitro, as reflected in significant rises in S protein-bound terminal complex (SC5b-9) and C3a-desarg levels.
Increasing the albumin content in serum by 1^4 g/100 ml led to 50^100% further increase in MLV-induced C activation, while
higher amounts of exogenous human serum albumin (HSA) gradually lost the capability to potentiate liposomal C
activation. HSA alone had no influence on SC5b-9 formation at any level below 12%. Complement activation by liposomes
and the potentiating effect of supplemental HSA were greatly reduced or eliminated in the absence of C1q or in the presence
of 10 mM EGTA/2.5 mM Mg2, pointing to the involvement of the classical pathway. Potentiation of C activation by
supplemental HSA was not unique to MLV-induced activation, as deposition of HSA on the membrane of ‘Centricon’
ultrafiltration units also potentiated the C-activating effect of the polycarbonate membrane. Fatty acid (FA) or non-
monomeric protein contamination in HSA were unlikely to be playing a role in the described effects, as 96% pure, FA-rich
(Buminate) and 99% pure, FA-free HSA had identical effects on liposomal C activation. While highlighting a new
modulatory mechanism on liposomal C activation, the above data raise the possibility that deposition of extravasated HSA
at sites of tissue injury may serve a hitherto unrecognized proinflammatory function. ß 2002 Elsevier Science B.V. All
rights reserved.
Keywords: Serum albumin; Liposome; Complement; In£ammation; Phospholipid bilayer; Polycarbonate membrane; Natural antibody
1. Introduction
It is known that liposomes, synthetic nanopar-
ticles, microspheres and essentially all foreign partic-
ulate substance exposed to blood can bind serum
albumin, along with a variety of other plasma pro-
teins, including immunoglobulins and complement
(C) [1^3]. The amount and spectrum of bound pro-
teins depend on the size, charge and other physico-
chemical characteristics of particles, and show sub-
stantial interspecies, individual and experimental
variation. In the case of anionic liposomes, the bind-
ing of albumin to the membrane was shown to be
substantial, and to involve both electrostatic and hy-
drophobic interactions [1,4,5]. Given the abundance
of albumin among plasma proteins and their prone-
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Abbreviations: C, complement; Chol, cholesterol; DMPC, di-
myristoyl phosphatidylcholine; DMPG, dimyristoyl phosphati-
dylglycerol; EGTA, ethyleneglycol tetraacetic acid; HSA, human
serum albumin; MLV, multilamellar vesicles; PBS, phosphate-
bu¡ered saline; SC5b-9, S protein-bound C5b-9
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ness to bind to liposomes, relatively little is known
about the in£uence of albumin on the association of
other proteins to liposomes, in particular, C proteins.
We became interested in this question following a
study in which we observed that co-incorporation
of human serum albumin (HSA) with hemoglobin
in liposomes led to substantial acceleration of C ac-
tivation by these vesicles relative to that observed
with only hemoglobin-containing control liposomes
[6]. This ¢nding was not explained previously, and
gave rise to the hypothesis that HSA exposed on the
liposome surface might accelerate C activation by the
phospholipid bilayer.
The present study was initiated to test the above
hypothesis. As C activator liposomes we used nega-
tively charged large multilamellar vesicles (MLV)
that contained 71 mol% cholesterol (Chol) in the
membrane, as these liposomes were shown in a pre-
vious study to be very e⁄cient C activators in pigs
[7]. The particular questions we addressed were:
(1) does supplementation of serum with HSA have
an in£uence on liposomal C activation; (2) if yes,
what are the characteristics of the e¡ect in regards
to HSA concentration dependence, activation path-
way involved, speci¢city to liposomal membranes
and the in£uence of HSA purity?
2. Materials and methods
2.1. Materials
Dimyristoyl phosphatidylcholine (DMPC), dimyr-
istoyl phosphatidylglycerol (DMPG) and cholesterol
(Chol) were purchased from Avanti Polar Lipids
(Alabaster, AL). HSA (Buminate 25%), prepared
by Cohn^Oncley fractionation of plasma, was from
Baxter Health (Glendale, CA). Fatty acid free HSA,
prepared from essentially globulin-free HSA and Zy-
mosan were from Sigma Chemical Co. (St. Louis,
MO). C1q-depleted human serum and the enzyme-
linked immunoassay (ELISA) kits for measuring
SC5b-9 and C3a-desarg were obtained from Quidel
Co. (San Diego, CA). MLV consisting of DMPC/
DMPG/Chol (24:5:71 mol%) were prepared by
thin-layer hydration/vortex mixing, as described pre-
viously in detail [7]. Human serum, obtained from
healthy volunteers as described earlier [6], was stored
at 370‡C until use.
2.2. Complement activation by liposomes þ HSA
Liposomes were incubated with serum in Eppen-
dorf tubes in a shaking water bath (80 cycles/min) for
30 min at 37‡C. Typically, to 35^40 Wl undiluted
serum the HSA, other additives (EGTA/Mg2) and
the activator (MLV, zymosan) were added to give a
¢nal volume of 50^120 Wl, using PBS for volume
control. The reaction was started by the addition of
the activator, and stopped by supplementing the vol-
ume to 1 ml by adding 880^950 Wl ‘sample diluent’ of
the SC5b-9 ELISA kit, which contained 10 mM
EDTA, 25 mg/ml bovine serum albumin, 0.05%
Tween 20 and 0.01% thimerosal (pH 7.4). C activa-
tion was quanti¢ed by measuring S protein-bound
terminal complex (SC5b-9) or C3a-desarg formation
by the respective ELISA kits, as described earlier [6].
2.3. Complement activation by polycarbonate
membranes þ HSA
Similar incubations as above were also performed
in sealed 10 kDa cuto¡ Centricon centrifugal ultra-
¢ltration units (Millipore Corp., Bedford, MA) in the
absence of liposomes, with HSA deposited on the
¢lter membrane prior to incubation. After rinsing
the Centricon unit with PBS, 2 mg HSA (in 100 Wl
PBS) was placed on the membrane and the unit was
centrifuged at 1500 rpm for 30 min to deposit the
protein on the ¢lter. This was followed by placing
100 Wl serum on the membrane, incubation and mea-
surement of SC5b-9 as described above. The controls
included serum incubated in Eppendorf tubes and on
¢lter without prior deposition of HSA on the mem-
brane.
2.4. Extraction of lipids from HSA
The lipid content of HSA was reduced by a single-
step extraction with chloroform/methanol (2:1 v/v).
The organic phase was dried in a Rotavapor and the
amount of extracted lipids was established from the
weight increase of the (dried) £ask relative to its pre-
experiment value.
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2.5. Statistical methods
The levels of SC5b-9 and C3a-desarg in serum
were expressed as mean þ S.D. for triplicate or qua-
druplicate wells. Signi¢cance of di¡erences between
two groups was determined by Student’s two-sample
t-test, and that among three groups was established
with analysis of variance (ANOVA) followed by the
Student^Newman^Keuls test.
3. Results
3.1. Complement activation by liposomes with and
without HSA
Fig. 1A shows that incubation of MLV with serum
led to a signi¢cant, 4-fold rise of SC5b-9 formation
relative to PBS control (P6 0.001), indicating C ac-
tivation by liposomes with subsequent formation of
the terminal complex. Addition of HSA (Buminate)
to the serum at 2% caused no activation by itself, but
together with MLV, 2% HSA caused a further 2-fold
increase of SC5b-9 formation relative that observed
with MLV alone, indicating potentiation of C acti-
vation by the liposomes. Fig. 1A also shows that
SC5b-9 formation was greatly reduced in the pres-
ence of 10 mM EGTA/2.5 mM Mg2 both in the
presence and absence of HSA, indicating a major
involvement of the classical pathway in liposome-in-
duced C activation and its potentiation by HSA.
Fig. 1B presents similar experiments in another
normal human serum, except that the amount of
added HSA was varied in the 0.5^6% range.
Although the baseline was somewhat higher in this
subject, the C-activating e¡ect of MLV and its po-
tentiation by 2% added HSA was qualitatively sim-
ilar. The experiment showed that 0.5% and 6% HSA
were ine¡ective in enhancing the C-activating e¡ect
of MLV, while 1% and 2% HSA were equipotent
enhancers. HSA alone caused no C activation at
2% and 6%.
The experiment shown in Fig. 2 essentially re-
peated Fig. 1B using yet another (third) human se-
Fig. 1. The in£uence of HSA on C activation by multilamellar
liposomes in human serum in vitro. (A) MLV was incubated
with undiluted human serum in the presence and absence of 2%
HSA and/or 10 mM EGTA/2.5 mM Mg2 as described in the
text. The bars show mean þ S.D. for triplicate determinations.
*Signi¢cant di¡erences between MLV and MLV+HSA vs. all
other groups (P6 0.01). **Signi¢cant di¡erences between
MLV+EGTA and MLV+HSA+EGTA vs. MLV and
MLV+HSA, respectively (P6 0.01), as determined by ANOVA
with subsequent pairwise comparisons using the Student^New-
man^Keuls test. (B) The concentration dependence of the po-
tentiating e¡ect of HSA on MLV-induced C activation in an-
other normal human serum. Similar experiment as shown in A,
except that the concentration of added HSA was varied as indi-
cated. *Signi¢cant di¡erence vs. all other groups except
MLV+4% HSA (P6 0.01).
Fig. 2. The in£uence of HSA on C activation by multilamellar
liposomes in human serum in vitro. Similar experiment as
shown in Fig. 1A,B, in yet another (third) serum. Here, in ad-
dition to SC5b-9, C3a-deasarg was also determined and the lev-
els of both markers were expressed as percentage of PBS base-
lines (which were 119.4 þ 7.7 and 4.8 þ 0.06 Wg/ml for C3a-
desarg and SC5b-9, respectively). *Signi¢cant di¡erences relative
to PBS; **signi¢cant di¡erences relative to MLV and
MLV+8% HSA (except SC5b-9 for MLV+8% HSA) at
(P6 0.05), as determined by ANOVA with subsequent pairwise
comparisons using the Student^Newman^Keuls test. Other de-
tails are the same as in Fig. 1.
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rum, and HSA doses 2%, 4%, 8% and 12%. In addi-
tion, we have tested the changes of C3a-desarg level,
which is another marker of C activation, a measure
of C3a anaphylatoxin production. In order to allow
direct comparison of the two analytes’ responses, we
converted their absolute serum levels to percent of
baseline. While corroborating the dose dependence
of the C activation-potentiating e¡ect of HSA in
the 1^4% range, the data demonstrated remarkable
parallelism between the changes of C3a-desarg and
SC5b-9, providing evidence that (1) the described C
activations were associated with anaphylatoxin pro-
duction, (2) the potentiation of MLV-induced SC5b-
9 production by HSA re£ected increased C activa-
tion, rather than modulation of the terminal pathway
only, and (3) SC5b-9 correlates with C3a production,
in addition to its established property of re£ecting
C5a formation. Taken together, it is unlikely that
the HSA-induced increase in MLV-induced SC5b-9
formation would be due to a change in the equilib-
rium between soluble (S-protein-bound) and mem-
brane-bound C5b-9, or that HSA would enhance
SC5b-9 formation directly, without increasing C3a
anaphylatoxin production.
3.2. Complement activation by polycarbonate
membranes with and without HSA precoating
In an attempt to establish whether or not the C
activation-potentiating e¡ect of HSA was restricted
to liposome-induced C activation, we used another
test system as well wherein serum was exposed to a
polycarbonate membrane surface with and without
prior coating of the membrane with HSA. More spe-
ci¢cally, serum was incubated in the sample holder of
polycarbonate membrane-based centrifugal ultra¢l-
tration (Centricon) units with and without precoat-
ing their membrane with an amount of HSA that is
present in the serum under conditions of potentiation
of liposomal C activation (2 mg). As shown in Fig. 3,
incubation of serum in Centricon units led to a mi-
nor, but statistically signi¢cant increase in SC5b-9
production relative to that observed with serum in-
cubated in Eppendorf tubes. This polycarbonate
membrane-induced C activation was signi¢cantly
greater in the case of HSA-precoated membranes,
providing qualitative evidence that the C activa-
tion-potentiating e¡ect of HSA was not restricted
to activation by liposomes. The HSA concentration
dependence and other quantitative details of C acti-
vation in the above Centricon system were not inves-
tigated further.
3.3. Complement activation by liposomes with and
without HSA in C1q-depleted serum
Fig. 4 shows that MLV with and without 2%
added HSA caused no rise in SC5b-9 when C1q-de-
pleted serum was used instead of whole serum. This
lack of response was not due to reduced levels or
function of C3 or the terminal cascade components,
as zymosan, a known alternative pathway activator,
Fig. 3. Complement activation by Centricon ¢lter membranes
with and without prior deposition of HSA on the membrane.
The membranes were rinsed with PBS and 2 mg HSA (100 Wl
from a 2% stock) was placed on the membrane followed by
centrifugation for 10 min at 4000 rpm at room temperature.
Human serum (100 Wl) was then incubated on the HSA-pre-
coated and non-precoated ¢lters as described in the text, while
control serum was incubated under identical conditions in Ep-
pendorf tubes. The serum remained on top of the membrane
without volume loss throughout the incubation regardless of
precoating with HSA. The measurement of SC5b-9 production
and other conditions of the experiments were the same as in
Fig. 1. *Signi¢cant di¡erence relative to serum incubated in Ep-
pendorf tube; **signi¢cant di¡erence relative to non-coated
Centricon membrane as determined by ANOVA with subse-
quent pairwise comparisons using the Student^Newman^Keuls
test.
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caused massive SC5b-9 production. Thus, C1q
played an essential role both in C activation by
MLV and its potentiation by HSA.
3.4. The role of fatty acid and non-monomeric protein
contaminations in the C activation-potentiating
e¡ect of HSA
HSA prepared by Cohn^Oncley fractionation of
plasma is known to contain free fatty acids (FA)
and non-monomeric protein contaminations (HSA
dimers and higher molecular mass proteins, mainly
globulins). The explore the possibility that the poten-
tiation of liposomal C activation by HSA might be
due to the above contaminating molecules, we com-
pared the e¡ects of Buminate, FA-depleted Buminate
and highly pure, FA-free HSA in similar experiments
as described in Figs. 1 and 2. As shown in Table 1,
the C activation-potentiating e¡ects of the three
preparations were essentially similar, arguing against
a major role of FA or non-monomeric components
in the observed e¡ects of HSA.
4. Discussion
The present study reports an unexpected potenti-
ating in£uence of HSA on C activation by multila-
mellar anionic liposomes and by a synthetic polycar-
bonate membrane. The C-activating e¡ect of certain
liposomes has been analyzed previously in numerous
laboratories and was established to involve a variety
of mechanisms and control factors (for review see
[8]). The high-cholesterol MLV we used in the
present study was reported recently to be a very
strong activator of pig C both in vivo and in vitro
[7], which was con¢rmed in human and rat serum as
well (Baranyi et al., submitted). Complement activa-
tion by the latter liposomes was shown to correlate
with their binding of naturally occurring anti-lipid
antibodies [7], which, together with the present ob-
servations on the inhibitory e¡ects of EGTA/Mg2
and C1q depletion, point to a major role of classical
pathway activation.
Table 1
Potentiation of liposome-induced C activation by HSA preparations of di¡erent purity and free fatty acid content
Purity (%) FA content (g/100 ml) SC5b-9 (Wg/ml)
Serum A Serum B
PBS 0.82 þ 0.42 1.91 þ 0.26
MLV 11.50 þ 0.59* 7.00 þ 0.67*
MLV+HSA (Buminate) 96a 0.29b 18.30 þ 0.51** 12.76 þ 1.61**
MLV+FA-depleted HSA 96a 0.10 18.39 þ 0.91**
MLV+FA-free HSA 99 6 0.001 15.20 þ 0.64**
Entries are mean þ S.D. for n = 3 wells in each group. *, **, signi¢cant di¡erence at P6 0.01 relative to PBS and MLV, respectively,
as determined by ANOVA followed by the Student^Newman^Keuls test. Multilamellar liposomes (MLV) þ 2% of the speci¢ed HSA
were incubated with two di¡erent sera (A and B), and SC5b-9 levels were measured as described in Section 2. The speci¢ed purity
and FA (octanoic acid) content of the di¡erent HSA preparations were either given in their label, or was measured as described in
Section 2.
aBuminate contained 96% HSA monomers, 2% dimers and 2% high molecular mass proteins (mainly globulins).
bObtained by conversion of 0.08 mmol octanoic acid/g (Mr of octanoic acid is 144.2).
Fig. 4. The role of C1q in MLV þ HSA-induced C activation.
Similar experiments as in Figs. 1 and 2, except that C1q-de-
pleted serum was used for the incubations. Zym þ HSA denote
5 mg/ml Zymosan þ 2% HSA. The rise they caused in SC5b-9
levels were signi¢cantly greater than in all other groups
(*P6 0.001) as determined by ANOVA with subsequent pair-
wise comparisons using the Student^Newman^Keuls test. HSA
caused no changes in Zym-induced C activation.
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In contrast to the above extensive information on
liposomal C activation, the observation that HSA
could modulate this activation has not been reported
before. Considering the wide use of HSA in human
therapy as a colloidal plasma expander with remark-
able safety record [9], it was unexpected that raising
the normal albumin level in serum (3.5^5%) by 1^4%
with a clinically used HSA preparation (Buminate)
would cause a signi¢cant increase in liposome-in-
duced elevation of serum SC5b-9, suggesting poten-
tiation of liposomal C activation.
In an attempt to understand the mechanism of the
phenomenon we raised and ruled out several possi-
bilities. Thus, the ¢ndings that the potentiating e¡ect
of HSA required C1q and Ca2, and that it was
manifested not only in increased SC5b-9 formation
but also in increased C3a-desarg generation, pointed
to stimulation of classical pathway C3 conversion
rather than the enhancement of terminal complex
formation. The facts that the relatively inhomogene-
ous, FA-rich Buminate, lipid-depleted Buminate and
the highly pure, FA-free HSA preparations had
quantitatively similar e¡ects on MLV-induced C ac-
tivation essentially ruled out a major causal role of
FA or non-monomeric protein components. We also
provided evidence that the enhancement of C activa-
tion by HSA was not speci¢c to phospholipid bilayer
vesicle membrane-induced activation but it was
present with a synthetic, £at and solid C activator
surface, raising the possibility that the phenomenon
may represent an universal positive feedback mecha-
nism of C ampli¢cation. The observation that HSA
alone did not cause C activation in the absence of a
C activator surface, taken together with the above
observations and considerations suggest that the C
activation-potentiating e¡ect of HSA may be due to
physical or physicochemical changes in its structure
following binding to the membrane.
Immune aggregates and many other large molec-
ular mass polymers can activate C via antibodies and
direct binding of C1q [10,11]. Of particular relevance
to the present study, Milich et al. [12] have demon-
strated that puri¢ed human C1q, immobilized on
polystyrene beads, bound polyalbumin, but not
monomeric albumin or polymers of various other
plasma proteins. Our data showing a key role of
C1q in both C activation and the potentiation of
MLV-induced C activation by HSA raises the possi-
bility that surface-bound HSA molecules polymerize,
or associate in aggregates, and bind C1q in a fashion
described in the above study [12] for polyalbumin.
This would lead to increased C activation relative
to that caused by C1q binding via anticholesterol
and antiphospholipid antibodies [6,7,13,14]. Based
on this explanation one may rationalize the gradual
decline of C activation-potentiation at HSA concen-
trations s 4% as a consequence of dissociation of
membrane-bound HSA^C1q complexes. Like with
circulating immune complexes, the formation of
HSA-C1q complexes may critically depend on the
relative concentrations of their components. After
saturating liposomal HSA binding sites at about
4% exogenous HSA, addition of further protein is
expected to increase the free to membrane-bound
HSA ratio, potentially destabilizing surface-bound
HSA^C1q complexes.
In addition to the above C1q-mechanism, a further
possible explanation for our observations is that
HSA increased C activation via increasing the bind-
ing of antibodies to the membranes. It is known that
the binding of antiphospholipid antibodies to their
phospholipid head group epitope critically depends
on the presence of another epitope, provided by L2-
glycoprotein I, which strongly interacts with phos-
pholipids via its hydrophobic lipid binding site (it
is also known as apolipoprotein H) [15]. Because
HSA, too, has capability for intense hydrophobic
interactions with lipids [4,5], in principle, mem-
brane-bound HSA complexes could bind excess
amounts of IgM-type antibodies via associative bind-
ing, in a fashion similar to that described for phos-
pholipid-L2^glycoprotein I complexes. One may also
speculate on the potential presence of naturally oc-
curring antibodies with reactivity to neoepitopes on
surface-bound (poly)albumin or aggregated albumin.
Polyalbumin appears to be prone for complex for-
mation with antibodies, as re£ected in reports on the
binding of polymerized HSA to hepatitis B surface
antigen (HBsAg) only in the presence of anti-HbsAg
IgM [16], or the binding of HSA-speci¢c antibodies
to erythrocyte-associated (aggregated) HSA but not
to soluble HSA [17,18]. These and possible other
hypotheses regarding the mechanism of the C activa-
tion-potentiating e¡ect of a limited amount of exog-
enous, membrane-deposited HSA remain to be ex-
plored in future studies.
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Concerning the practical implications of our study,
besides its wide use as a plasma expander [9], HSA
has been studied as a potential carrier system for
various therapeutic agents, based on the expectation
that nanoparticles and microspheres made from al-
bumin are biodegradable and may provide long cir-
culation time for the associated agents [19^24]. The
present results highlight a potential problem with
HSA-based carrier systems, inasmuch as unforeseen
acceleration of C activation may not only counteract
circulation longevity but may cause anaphylactoid
reactions or other nonspeci¢c ‘pseudoallergic’ symp-
toms (recently called C activation-related pseudoal-
lergy (CARPA) [7].
Finally, our data raise the possibility that albumin
may play a hitherto unrecognized proin£ammatory
function by promoting C activation at sites of mas-
sive extravasation of proteins and deposition in in-
jured tissues, such as occur upon traumatic hemor-
rhage or exudative in£ammation. The resultant
increase in chemotactic anaphylatoxins would recruit
granulocytes and macrophages, thereby accelerating
the in£ammatory process.
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